CN109761974B - 1,2,3, 4-tetrahydro-9H-pyrido [3,4-b ] indole TRPV1 antagonist and application thereof - Google Patents
1,2,3, 4-tetrahydro-9H-pyrido [3,4-b ] indole TRPV1 antagonist and application thereof Download PDFInfo
- Publication number
- CN109761974B CN109761974B CN201910053921.7A CN201910053921A CN109761974B CN 109761974 B CN109761974 B CN 109761974B CN 201910053921 A CN201910053921 A CN 201910053921A CN 109761974 B CN109761974 B CN 109761974B
- Authority
- CN
- China
- Prior art keywords
- indole
- pyrido
- tetrahydro
- methyl
- triazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZXLDQJLIBNPEFJ-UHFFFAOYSA-N tetrahydro-beta-carboline Natural products C1CNC(C)C2=C1C1=CC=C(OC)C=C1N2 ZXLDQJLIBNPEFJ-UHFFFAOYSA-N 0.000 title claims abstract description 20
- CFTOTSJVQRFXOF-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CNCC2 CFTOTSJVQRFXOF-UHFFFAOYSA-N 0.000 title claims abstract description 19
- PJAAESPGJOSQGZ-DZGBDDFRSA-N Isovelleral Chemical compound O=CC1=C[C@@H]2CC(C)(C)C[C@@H]2[C@@]2(C)C[C@]21C=O PJAAESPGJOSQGZ-DZGBDDFRSA-N 0.000 title claims description 12
- 229940126422 TRPV1 antagonist Drugs 0.000 title claims description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 48
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims description 58
- PCRZAERIRCDHEK-UHFFFAOYSA-N 2-[[1-(4-chlorophenyl)triazol-4-yl]methyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1)CN1CC=2NC3=CC=CC=C3C=2CC1 PCRZAERIRCDHEK-UHFFFAOYSA-N 0.000 claims description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- YOCCCENRKHPMQA-UHFFFAOYSA-N 2-[(1-isoquinolin-5-yltriazol-4-yl)methyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole Chemical compound C1=NC=CC2=C(C=CC=C12)N1N=NC(=C1)CN1CC=2NC3=CC=CC=C3C=2CC1 YOCCCENRKHPMQA-UHFFFAOYSA-N 0.000 claims description 6
- DSUPVDBHPKQMRK-UHFFFAOYSA-N 2-[[1-(2,4,6-trimethylphenyl)triazol-4-yl]methyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole Chemical compound C1(=C(C(=CC(=C1)C)C)N1N=NC(=C1)CN1CC=2NC3=CC=CC=C3C=2CC1)C DSUPVDBHPKQMRK-UHFFFAOYSA-N 0.000 claims description 6
- JKDSCLCWDOLPRY-UHFFFAOYSA-N 2-[[1-(2-chlorophenyl)triazol-4-yl]methyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole Chemical compound ClC1=C(C=CC=C1)N1N=NC(=C1)CN1CC=2NC3=CC=CC=C3C=2CC1 JKDSCLCWDOLPRY-UHFFFAOYSA-N 0.000 claims description 6
- YSDRBTHXMBWGEC-UHFFFAOYSA-N 2-[[1-(2-chloropyridin-3-yl)triazol-4-yl]methyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole Chemical compound ClC1=NC=CC=C1N1N=NC(=C1)CN1CC=2NC3=CC=CC=C3C=2CC1 YSDRBTHXMBWGEC-UHFFFAOYSA-N 0.000 claims description 6
- SHDVFZWDYUPULV-UHFFFAOYSA-N 2-[[1-(3,4-dimethoxyphenyl)triazol-4-yl]methyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole Chemical compound COC=1C=C(C=CC=1OC)N1N=NC(=C1)CN1CC=2NC3=CC=CC=C3C=2CC1 SHDVFZWDYUPULV-UHFFFAOYSA-N 0.000 claims description 6
- CGLRNMZXRLYLKI-UHFFFAOYSA-N 2-[[1-(3-chloro-4-methylphenyl)triazol-4-yl]methyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole Chemical compound ClC=1C=C(C=CC=1C)N1N=NC(=C1)CN1CC=2NC3=CC=CC=C3C=2CC1 CGLRNMZXRLYLKI-UHFFFAOYSA-N 0.000 claims description 6
- RZLSBBVZWUHNTN-UHFFFAOYSA-N 2-[[1-(3-fluorophenyl)triazol-4-yl]methyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole Chemical compound FC=1C=C(C=CC=1)N1N=NC(=C1)CN1CC=2NC3=CC=CC=C3C=2CC1 RZLSBBVZWUHNTN-UHFFFAOYSA-N 0.000 claims description 6
- ZIJMNLRVDIZNJE-UHFFFAOYSA-N 2-[[1-(3-propan-2-ylphenyl)triazol-4-yl]methyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole Chemical compound C(C)(C)C=1C=C(C=CC=1)N1N=NC(=C1)CN1CC=2NC3=CC=CC=C3C=2CC1 ZIJMNLRVDIZNJE-UHFFFAOYSA-N 0.000 claims description 6
- KNXIBGKHVKTOCF-UHFFFAOYSA-N 2-[[1-(4,6-dimethylpyridin-2-yl)triazol-4-yl]methyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole Chemical compound CC1=CC(=NC(=C1)C)N1N=NC(=C1)CN1CC=2NC3=CC=CC=C3C=2CC1 KNXIBGKHVKTOCF-UHFFFAOYSA-N 0.000 claims description 6
- UVMHTWNWLFNCOE-UHFFFAOYSA-N 2-[[1-(4-methyl-2-nitrophenyl)triazol-4-yl]methyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole Chemical compound CC1=CC(=C(C=C1)N1N=NC(=C1)CN1CC=2NC3=CC=CC=C3C=2CC1)[N+](=O)[O-] UVMHTWNWLFNCOE-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- 239000000730 antalgic agent Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 229940035676 analgesics Drugs 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 2
- 229960004106 citric acid Drugs 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 229960000448 lactic acid Drugs 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 229940098895 maleic acid Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 229940107700 pyruvic acid Drugs 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 229960001367 tartaric acid Drugs 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- RERZNCLIYCABFS-UHFFFAOYSA-N harmaline Chemical compound C1CN=C(C)C2=C1C1=CC=C(OC)C=C1N2 RERZNCLIYCABFS-UHFFFAOYSA-N 0.000 claims 1
- 229940124583 pain medication Drugs 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
- 229960005137 succinic acid Drugs 0.000 claims 1
- -1 phenoxy, acetyl Chemical group 0.000 abstract description 19
- 102000003566 TRPV1 Human genes 0.000 abstract description 16
- 101150016206 Trpv1 gene Proteins 0.000 abstract description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 15
- 238000012360 testing method Methods 0.000 abstract description 15
- 230000000202 analgesic effect Effects 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 11
- ROGUAPYLUCHQGK-UHFFFAOYSA-N 1-piperazinecarboxamide, 4-(3-chloro-2-pyridinyl)-n-[4-(1,1-dimethylethyl)phenyl]- Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)N1CCN(C=2C(=CC=CN=2)Cl)CC1 ROGUAPYLUCHQGK-UHFFFAOYSA-N 0.000 abstract description 9
- 108010025083 TRPV1 receptor Proteins 0.000 abstract description 9
- 239000005557 antagonist Substances 0.000 abstract description 8
- 230000036760 body temperature Effects 0.000 abstract description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 abstract description 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 abstract description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 abstract description 2
- 125000004076 pyridyl group Chemical group 0.000 abstract description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract description 2
- 125000003831 tetrazolyl group Chemical group 0.000 abstract description 2
- 125000001425 triazolyl group Chemical group 0.000 abstract description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 48
- 239000007787 solid Substances 0.000 description 41
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 32
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 14
- 230000036407 pain Effects 0.000 description 14
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 229960002504 capsaicin Drugs 0.000 description 9
- 235000017663 capsaicin Nutrition 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 8
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
- 208000000114 Pain Threshold Diseases 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000037040 pain threshold Effects 0.000 description 6
- MGRYOJBTSRCUMO-UHFFFAOYSA-N 2-[[1-(4-nitrophenyl)triazol-4-yl]methyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole Chemical compound [N+](=O)([O-])C1=CC=C(C=C1)N1N=NC(=C1)CN1CC=2NC3=CC=CC=C3C=2CC1 MGRYOJBTSRCUMO-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- HZVGOEUGZJFTNN-UHFFFAOYSA-N 1-azido-4-chlorobenzene Chemical compound ClC1=CC=C(N=[N+]=[N-])C=C1 HZVGOEUGZJFTNN-UHFFFAOYSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- CZZZABOKJQXEBO-UHFFFAOYSA-N 2,4-dimethylaniline Chemical group CC1=CC=C(N)C(C)=C1 CZZZABOKJQXEBO-UHFFFAOYSA-N 0.000 description 2
- MEQBJJUWDCYIAB-UHFFFAOYSA-N 2-chloropyridin-3-amine Chemical group NC1=CC=CN=C1Cl MEQBJJUWDCYIAB-UHFFFAOYSA-N 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 2
- RQKFYFNZSHWXAW-UHFFFAOYSA-N 3-chloro-p-toluidine Chemical group CC1=CC=C(N)C=C1Cl RQKFYFNZSHWXAW-UHFFFAOYSA-N 0.000 description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 2
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 2
- 108010000239 Aequorin Proteins 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- YHIPILPTUVMWQT-UHFFFAOYSA-N Oplophorus luciferin Chemical compound C1=CC(O)=CC=C1CC(C(N1C=C(N2)C=3C=CC(O)=CC=3)=O)=NC1=C2CC1=CC=CC=C1 YHIPILPTUVMWQT-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical group C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical group CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical group O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical group CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical group CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- 150000000177 1,2,3-triazoles Chemical class 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- XXFUZSHTIOFGNV-UHFFFAOYSA-N 1-bromoprop-1-yne Chemical compound CC#CBr XXFUZSHTIOFGNV-UHFFFAOYSA-N 0.000 description 1
- KWVPRPSXBZNOHS-UHFFFAOYSA-N 2,4,6-Trimethylaniline Chemical group CC1=CC(C)=C(N)C(C)=C1 KWVPRPSXBZNOHS-UHFFFAOYSA-N 0.000 description 1
- NATVSFWWYVJTAZ-UHFFFAOYSA-N 2,4,6-trichloroaniline Chemical group NC1=C(Cl)C=C(Cl)C=C1Cl NATVSFWWYVJTAZ-UHFFFAOYSA-N 0.000 description 1
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 1
- AKCRQHGQIJBRMN-UHFFFAOYSA-N 2-chloroaniline Chemical group NC1=CC=CC=C1Cl AKCRQHGQIJBRMN-UHFFFAOYSA-N 0.000 description 1
- DLURHXYXQYMPLT-UHFFFAOYSA-N 2-nitro-p-toluidine Chemical group CC1=CC=C(N)C([N+]([O-])=O)=C1 DLURHXYXQYMPLT-UHFFFAOYSA-N 0.000 description 1
- LGDHZCLREKIGKJ-UHFFFAOYSA-N 3,4-dimethoxyaniline Chemical group COC1=CC=C(N)C=C1OC LGDHZCLREKIGKJ-UHFFFAOYSA-N 0.000 description 1
- AVZCPICCWKMZDT-UHFFFAOYSA-N 3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid Chemical compound N=1C(NCCC(=O)O)=CC(N2CCC3=CC=CC=C3CC2)=NC=1C1=CC=CC=N1 AVZCPICCWKMZDT-UHFFFAOYSA-N 0.000 description 1
- QZVQQUVWFIZUBQ-UHFFFAOYSA-N 3-fluoroaniline Chemical group NC1=CC=CC(F)=C1 QZVQQUVWFIZUBQ-UHFFFAOYSA-N 0.000 description 1
- XCCNRBCNYGWTQX-UHFFFAOYSA-N 3-propan-2-ylaniline Chemical group CC(C)C1=CC=CC(N)=C1 XCCNRBCNYGWTQX-UHFFFAOYSA-N 0.000 description 1
- BRBUBVKGJRPRRD-UHFFFAOYSA-N 4,6-dimethylpyridin-2-amine Chemical group CC1=CC(C)=NC(N)=C1 BRBUBVKGJRPRRD-UHFFFAOYSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical group NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- WRDWWAVNELMWAM-UHFFFAOYSA-N 4-tert-butylaniline Chemical group CC(C)(C)C1=CC=C(N)C=C1 WRDWWAVNELMWAM-UHFFFAOYSA-N 0.000 description 1
- ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical group NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 description 1
- DTVYNUOOZIKEEX-UHFFFAOYSA-N 5-aminoisoquinoline Chemical group N1=CC=C2C(N)=CC=CC2=C1 DTVYNUOOZIKEEX-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- TXDUTHBFYKGSAH-SFHVURJKSA-N Evodiamine Chemical compound C1=CC=C2N(C)[C@@H]3C(NC=4C5=CC=CC=4)=C5CCN3C(=O)C2=C1 TXDUTHBFYKGSAH-SFHVURJKSA-N 0.000 description 1
- HMXRXBIGGYUEAX-SFHVURJKSA-N Evodiamine Natural products CN1[C@H]2N(CCc3[nH]c4ccccc4c23)C(=O)c5ccccc15 HMXRXBIGGYUEAX-SFHVURJKSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108010062740 TRPV Cation Channels Proteins 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical group O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical group OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- WAAPRVJPNKAMQT-UHFFFAOYSA-N isoquinoline-1,3,4,5,6-pentamine Chemical group C1=CC(=C(C2=C1C(=NC(=C2N)N)N)N)N WAAPRVJPNKAMQT-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical group C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000004084 narcotic analgesic agent Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000003962 neuroinflammatory response Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 210000002248 primary sensory neuron Anatomy 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 210000000413 sensory ganglia Anatomy 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 210000000427 trigeminal ganglion Anatomy 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明涉及1,2,3,4‑四氢‑9H‑吡啶并[3,4‑b]吲哚类TRPV1拮抗剂或其药学上可接受的盐，结构通式如下：式中，R为H、F、Cl、Br、I、CF3、甲基、异丙基、叔丁基、环丙基、丙烯基、乙炔基、羟基、苯氧基、乙酰基或苯基；n为1、2或3；L为三氮唑基、四氮唑基、脲基或硫脲基；Ar为苯基、吡啶基、异喹啉基、喹啉基或嘧啶基。经试验发现：该类1,2,3,4‑四氢‑9H‑吡啶并[3,4‑b]吲哚类化合物具有良好的TRPV1抑制活性，且部分化合物活性远高于TRPV1受体拮抗剂BCTC；与BCTC相比几乎无体温升高副作用。因此本发明所述通式1,2,3,4‑四氢‑9H‑吡啶并[3,4‑b]吲哚类化合物及其药用盐安全有效，具有较强的镇痛作用。The present invention relates to 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole TRPV1 antagonists or pharmaceutically acceptable salts thereof, and the general structural formula is as follows: 
where R is H, F, Cl, Br, I, CF 3 , methyl, isopropyl, tert-butyl, cyclopropyl, propenyl, ethynyl, hydroxyl, phenoxy, acetyl or phenyl ; n is 1, 2 or 3; L is triazolyl, tetrazolyl, ureido or thioureido; Ar is phenyl, pyridyl, isoquinolinyl, quinolinyl or pyrimidinyl. Tests have found that these 1,2,3,4-tetrahydro- 9H -pyrido[3,4-b]indole compounds have good TRPV1 inhibitory activity, and some compounds have activities much higher than TRPV1 receptors Antagonist BCTC; almost no side effects of elevated body temperature compared with BCTC. Therefore, the compounds of the general formula 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole and their medicinal salts described in the present invention are safe and effective, and have strong analgesic effects.
Description
Technical Field
The invention belongs to the technical field of pharmaceutical chemistry, and particularly relates to 1,2,3, 4-tetrahydro-9H-pyrido [3,4-b ] indole TRPV1 antagonists, a pharmaceutical preparation using the compounds as active ingredients, and application of the compounds in preparation of a pain treatment drug.
Background
Pain is a common symptom of many diseases, and approximately 5 million people suffer from a variety of pain each year. Currently, the analgesics most clinically used are mainly divided into two categories: one is a narcotic analgesic that directly activates opioid receptors, and the other is an antipyretic analgesic represented by non-steroidal anti-inflammatory drugs (NSAIDs). Although the clinical effects of the medicines are good, the side effects of the medicines are obvious, such as addiction to opioids, gastrointestinal side effects of non-steroidal anti-inflammatory drugs and the like. In addition, a large number of pains such as chronic and neuropathic pains cannot be effectively controlled using existing drugs.
In recent years, with the development of related disciplines and the application of new technologies, research on various receptors related to pain transduction and their selective ligands has been advanced. In 1997, David juliuus and his panelists successfully cloned transient receptor potential vanilloid 1(TRPV1, once referred to as capsaicin receptor or vanilloid receptor subtype 1), a breakthrough in the field of neurobiology and pain research. TRPV1 is widely distributed on primary sensory neurons such as the two-stage neurons without myelinated axons (C fibers), the intracellular sensory ganglia (dorsal root ganglia and trigeminal ganglia) and the subset of sensory neurons with thin myelinated axons (a δ fibers), and plays a critical role in the initiation of the neuroinflammatory response and in the transduction of pain. At present, TRPV1 has become an important novel analgesic target, and its antagonist can directly block receptor, inhibit the transmission of pain signal from peripheral nerve to central nerve, block various pathological states related to receptor, and has analgesic effect. Different from the traditional analgesic agent for blocking the transmission of pain, the TRPV1 antagonist acts on peripheral nociceptors, can directly block the perception of pain, and has more direct analgesic effect. The study of TRPV1 antagonists has become one of the most promising analgesic research directions today.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides 1,2,3, 4-tetrahydro-9H-pyrido [3,4-b ] indole TRPV1 antagonists, which can be used for preparing novel analgesic drugs.
The invention also provides a preparation method of the 1,2,3, 4-tetrahydro-9H-pyrido [3,4-b ] indole TRPV1 antagonist, a pharmaceutical preparation taking the compound as an active ingredient, and application of the compound in preparation of a medicament for treating pain.
In order to achieve the purpose, the invention adopts the following technical scheme:
the invention synthesizes a series of 1,2,3, 4-tetrahydro-9H-pyrido [3,4-b ] indole TRPV1 antagonists shown in a general formula (I) or pharmaceutically acceptable salts thereof, and the specific structural general formula is as follows:
mother nucleus 1,2,3, 4-tetrahydro-9H-pyrido [3,4-b ]]In the indole, R on the left side is H, F, Cl, Br, I, CF3Aromatic or aliphatic (e.g., methyl, isopropyl, t-butyl, cyclopropyl, propenyl, ethynyl, hydroxy, phenoxy, acetyl or phenyl, etc.), n is 1,2 or 3 (i.e., the number of rings on the right can be varied, e.g., six-membered, seven-membered, eight-membered, etc.); l may be: groups such as triazolyl, tetrazolyl, ureido, or thioureido groups; ar can be a benzene ring or an aromatic heterocyclic group, such as phenyl, pyridyl, isoquinolyl, quinolyl or pyrimidyl and the like, and the position of a substituent on the aromatic can be changed.
Further, preferred compounds among the 1,2,3, 4-tetrahydro-9H-pyrido [3,4-b ] indole TRPV1 antagonists of the present invention described above include, but are not limited to, the following twenty compounds:
2- ((1- (4-chlorophenyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (1);
2- ((1- (isoquinolin-5-yl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (2);
2- ((1- (2-chlorophenyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (3);
2- ((1- (2-nitro-4-methylphenyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (4);
2- ((1- (3-chloro-4-methylphenyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (5);
2- ((1- (3-fluorophenyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (6);
2- ((1- (4-nitrophenyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (7);
2- ((1- (2,4, 6-trimethylphenyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (8);
2- ((1- (3, 4-dimethoxyphenyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (9);
2- ((1- (3-isopropylphenyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (10);
2- ((1- (4, 6-dimethylpyridinyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (11);
2- ((1- (2-chloropyridyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (12);
n- (4-bromophenyl) -3, 4-dihydro-1H-pyrido [3,4-b ] indole-2 (9H) -amide (13);
n- (isoquinolin-5-yl) -3, 4-dihydro-1H-pyrido [3,4-b ] indole-2 (9H) -amide (14);
n- (2-chloropyridin-3-yl) -3, 4-dihydro-1H-pyrido [3,4-b ] indole-2 (9H) -amide (15);
n- (2-chloro-4-methylphenyl) -3, 4-dihydro-1H-pyrido [3,4-b ] indole-2 (9H) -amide (16);
n- (4-tert-butylphenyl) -3, 4-dihydro-1H-pyrido [3,4-b ] indole-2 (9H) -amide (17);
n- (4-trifluoromethylphenyl) -3, 4-dihydro-1H-pyrido [3,4-b ] indole-2 (9H) -amide (18);
n- (2,4, 6-trichlorophenyl) -3, 4-dihydro-1H-pyrido [3,4-b ] indole-2 (9H) -amide (19) or
N- (2, 4-dimethylphenyl) -3, 4-dihydro-1H-pyrido [3,4-b ] indole-2 (9H) -amide (20).
The 1,2,3, 4-tetrahydro-9H-pyrido [3,4-b ] indole TRPV1 antagonist or a pharmaceutically acceptable salt thereof comprises an addition salt formed by the following acids: hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid, acetic acid, trifluoroacetic acid, pyruvic acid, citric acid, tartaric acid, lactic acid, maleic acid, benzenesulfonic acid or succinic acid, and the like known to be acceptable.
The invention provides a compound preparation prepared by compounding the 1,2,3, 4-tetrahydro-9H-pyrido [3,4-b ] indole TRPV1 antagonist or pharmaceutically acceptable salt thereof with conventional auxiliary materials or carriers in the field. The preparation comprises a compound shown as a general formula (I) or a medicinal salt thereof as an effective component and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are those conventional in the pharmaceutical art and refer to one or more inert, non-toxic solid or liquid fillers, diluents, adjuvants and the like that do not adversely affect the active compound or the patient.
The dosage form of the compound preparation can be tablets, capsules, pills, suppositories, soft capsules, oral liquid, suspensions, injections and other pharmaceutically common dosage forms. Tablets and capsules for oral use contain conventional excipients such as fillers, diluents, lubricants, dispersants and binders. The various dosage forms of the compound preparation of the present invention can be prepared according to conventional methods well known in the pharmaceutical field.
The dosage of the above active ingredients may vary depending on the formulation. In general, amounts which have proven advantageous are, for achieving the desired result, from about 0.01 to 800mg, preferably from 0.1 to 80mg/kg, of the compound of the formula (I) per kg of compound to be administered per 24 hours. If necessary, it can be administered in the form of several single doses. However, if necessary, it may deviate from the above amounts depending on the type and body weight of the subject to be treated, the behavior of the individual on the drug, the nature and severity of the disease, the type of preparation and administration, and the time and interval of administration.
The invention also provides application of the 1,2,3, 4-tetrahydro-9H-pyrido [3,4-b ] indole TRPV1 antagonist or pharmaceutically acceptable salts thereof in preparing a medicament for treating pain.
The invention also provides the application of the compound preparation as an analgesic.
The preparation of the 1,2,3, 4-tetrahydro-9H-pyrido [3,4-b ] indole compound is divided into the following two synthetic routes, wherein the synthetic routes of the 1,2, 3-triazole compounds such as the compounds (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11) and (12) are shown as follows:
the synthetic routes of urea compounds such as compounds (13), (14), (15), (16), (17), (18), (19), (20) are shown below:
the invention provides a 1,2,3, 4-tetrahydro-9H-pyrido [3,4-b ] indole compound with a novel structure, which is obtained by modifying a common structural segment of a main active ingredient Evodiamine and rutaceae apine which have multiple biological activities such as analgesia, anti-inflammation, anti-diabetes, thermoregulation and the like related to TRPV1 activity when researching the traditional Chinese medicine fructus evodiae, and solves the problems of drug property, water solubility, oral bioavailability and the like of the traditional medicine through modification of a connecting arm and an aromatic region functional group and modification of an effective group. The 1,2,3, 4-tetrahydro-9H-pyrido [3,4-b ] indole compounds have good TRPV1 inhibitory activity, and the activity of partial compounds is far higher than that of a TRPV1 receptor antagonist BCTC; there were few adverse effects of body temperature elevation compared to BCTC. Therefore, the general formula 1,2,3, 4-tetrahydro-9H-pyrido [3,4-b ] indole compound and the medicinal salt thereof are safe and effective and have strong analgesic effect.
Detailed Description
The present invention will be further described with reference to the following examples. It should be noted that the following examples are only for illustration and are not intended to limit the present invention. Variations of the teachings of the present invention may be made by those skilled in the art without departing from the scope of the claims of the present application.
Example 1:
preparation of 2- ((1- (4-chlorophenyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (1)
(a) Preparation of 1-azido-4-chlorobenzene
Parachloroaniline (1.27g,10mmol) dissolved in 6mol/L HCl (10mL) in a round bottom flask under ice bath, NaNO was placed2(0.69g, 10mmol) was dissolved in 25ml of water and added dropwise to the reaction system. The mixture was stirred for 20min with NaN3(1.95g, 30mmol) was dissolved in 40ml of water and added dropwise. Stirring at room temperature for 2-4h, extracting with ethyl acetate (30ml × 2), mixing organic phases, washing with water (30ml × 3), and removing solvent by evaporation under reduced pressure to obtain 1-azido-4-chlorobenzene;
(b) preparation of 2- (prop-2-yn-1-yl) -2,3,4, 9-tetrahydro-9H-pyrido [3,4-b ] indole
1,2,3, 4-tetrahydro-9H-pyrido [3,4-b ]]Indole (1.72g,10mmol), K2CO3(0.69g,0.5mmol) was dissolved in acetone (10ml) to obtain solution A. Bromopropyne (1.18g,10mmol) and KI (0.018g,0.01mmol) were dissolved in acetone (10ml) to obtain a solution B. Stirring the solution A, B for 45min, adding the solution B into the solution A dropwise, stirring for 12-24H, vacuum filtering, and removing solvent by evaporation under reduced pressure to obtain 2- (prop-2-yne-1-yl) -2,3,4, 9-tetrahydro-9H-pyrido [3,4-B ]]Indole;
(c) preparation of 2- ((1- (4-chlorophenyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (1)
1-azido-4-chlorobenzene (1.53g, 10mmol) was reacted with 2- (prop-2-yn-1-yl) -2,3,4, 9-tetrahydro-9H-pyrido [3,4-b ] indole (2.10g, 10mmol) in 75% methanol (40ml) with heating at 60 ℃ for 24-48H. Extraction with ethyl acetate (30ml × 2), combination of the organic phases, evaporation of the solvent under reduced pressure and column separation (DCM: MeOH ═ 20:1 by volume) gave compound 1 as a pale yellow solid in 83% yield. The experimental data are as follows:
C20H18ClN5,yield 83％,pale yellow solid,m.p＝237.0-237.2℃；1H NMR(DMSO,400MHz):δppm 10.69(s,1H,NH),8.82(s,1H,C＝CH),7.98(d,2H,J＝8.0Hz,Ar-H),7.66(d,2H,J＝8.0Hz,Ar-H),7.36(d,1H,J＝8.0Hz,Ar-H),7.27(d,1H,J＝8.0Hz,Ar-H),7.01(t,1H,J＝8.0Hz,Ar-H),6.94(t,1H,J＝8.0Hz,Ar-H),3.94(s,2H,CH2),3.70(s,2H,CH2),2.88(t,2H,J＝6.0Hz,CH2),2.72(t,2H,J＝6.0Hz,CH2)；HRMS m/z:[M+H]+364.1320(calcd.364.1323)。
example 2:
preparation of 2- ((1- (isoquinolin-5-yl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (2)
Referring to the preparation method in example 1, wherein p-chloroaniline was replaced with pentaaminoisoquinoline, compound 2 was prepared as a tan solid in 87% yield. The experimental data are as follows:
C23H20N6,yield 87％,brown yellow solid,m.p＝147.2-149.6℃；1H NMR(CDCl3,400MHz):δppm 9.33(s,1H,NH),8.70(s,1H,C＝CH),8.54(s,1H,Ar-H),8.09(d,1H,J＝12.0Hz,Ar-H),7.91(s,1H,Ar-H),7.73-7.63(m,2H,Ar-H),7.54(d,1H,J＝8.0Hz,Ar-H),7.44(d,1H,J＝12.0Hz,Ar-H),7.24(t,1H,J＝8.0Hz,Ar-H),7.10-7.01(m,2H,Ar-H),4.05(s,2H,CH2),3.79(s,2H,CH2),3.02(t,2H,J＝6.0Hz,CH2),2.86(t,2H,J＝6.0Hz,CH2)；HRMS m/z:[M+H]+381.1819(calcd.381.1822)。
example 3:
preparation of 2- ((1- (2-chlorophenyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (3)
Referring to the preparation method in example 1, wherein p-chloroaniline was replaced with o-chloroaniline, compound 3 was obtained as a pale yellow solid in a yield of 91.6%. The experimental data are as follows:
C20H18ClN5,yield 91.6％,pale yellow solid,m.p＝143.6-145.0℃；1H NMR(DMSO,400MHz):δppm 10.62(s,1H,NH),8.42(s,1H,C＝CH),7.68(d,1H,J＝8.0Hz,Ar-H),7.62(d,1H,J＝12.0Hz,Ar-H),7.52(t,2H,J＝10.0Hz,Ar-H),7.27(d,1H,J＝8.0Hz,Ar-H),7.18(t,1H,J＝12.0Hz,Ar-H),6.94-6.82(m,2H,Ar-H),3.87(s,2H,CH2),3.60(s,2H,CH2),2.79(t,2H,J＝8.0Hz,CH2),2.65(t,2H,J＝14.0Hz,CH2)；HRMS m/z:[M+H]+364.1319(calcd.364.1323)。
example 4:
preparation of 2- ((1- (2-nitro-4-methylphenyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (4)
Referring to the preparation method in example 1, wherein p-chloroaniline was replaced with 2-nitro-4-methylaniline, compound 4 was obtained as a tan solid in a yield of 92.0%. The experimental data are as follows:
C21H20N6O2,yield 92.0％,brown yellow solid,m.p＝128.7-129.4℃；1H NMR(DMSO,400MHz):δppm 10.73(s,1H,NH),8.60(s,1H,C＝CH),8.05(d,2H,J＝8.0Hz,Ar-H),7.74(s,2H,Ar-H),7.37(d,1H,J＝8.0Hz,Ar-H),7.28(d,1H,J＝8.0Hz,Ar-H),7.02(t,1H,J＝8.0Hz,Ar-H),6.95(t,1H,J＝8.0Hz,Ar-H),3.97(s,2H,CH2),3.71(s,2H,CH2),2.89(t,2H,J＝6.0Hz,CH2),2.74(t,2H,J＝6.0Hz,CH2),2.50(s,3H,CH3)；HRMS m/z:[M+H]+389.1719(calcd.389.1721).
example 5:
preparation of 2- ((1- (3-chloro-4-methylphenyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (5)
Referring to the preparation method in example 1, wherein p-chloroaniline was replaced with 3-chloro-4-methylaniline, compound 5 was obtained as a tan solid in a yield of 90.3%. The experimental data are as follows:
C21H20ClN5,yield 90.3％,brown yellow solid,m.p＝229.6-231.4℃；1H NMR(DMSO,400MHz):δppm 10.80(s,1H,NH),8.96(s,1H,C＝CH),8.16(s,1H,Ar-H),7.96(d,1H,J＝8.0Hz,Ar-H),7.67(d,1H,J＝8.0Hz Ar-H),7.47(d,1H,J＝8.0Hz,Ar-H),7.38(d,1H,J＝8.0Hz,Ar-H),7.12(t,1H,J＝8.0Hz,Ar-H),7.05(t,1H,J＝8.0Hz,Ar-H),4.05(s,2H,CH2),3.81(s,2H,CH2),3.48(s,3H,CH3),3.00(s,2H,CH2),2.84(s,2H,CH3)；HRMS m/z:[M+H]+378.1480(calcd.378.1480).
example 6:
preparation of 2- ((1- (3-fluorophenyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (6)
Referring to the preparation method in example 1, in which p-chloroaniline was replaced with m-fluoroaniline, compound 6 was obtained as a tan solid in a yield of 92.4%. The experimental data are as follows:
C20H18FN5,yield 92.4％,brown yellow solid,m.p＝196.1-198.2℃；1H NMR(DMSO,400MHz):δppm 10.68(s,1H,NH),8.86(s,1H,C＝CH),7.89-7.86(m,2H,Ar-H),7.64(d,1H,Ar-H),7.38-7.27(m,3H,Ar-H),7.03-6.92(m,2H,Ar-H),3.95(s,2H,CH2),3.71(s,2H,CH2),2.89(s,2H,CH2),2.73(s,2H,CH2)；HRMS m/z:[M+H]+348.1618(calcd.348.1619).
example 7:
preparation of 2- ((1- (4-nitrophenyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (7)
Referring to the preparation method in example 1, wherein p-chloroaniline was replaced with p-nitroaniline, compound 7 was obtained as a tan solid in 89.2% yield. The experimental data are as follows:
C20H18N6O2,yield 89.2％,brown yellow solid,m.p＝201.4-202.5℃；1H NMR(DMSO,400MHz):δppm 10.65(s,1H,NH),9.00(s,1H,C＝CH),8.44(d,2H,J＝12.0Hz,Ar-H),8.26(t,2H,J＝6.0Hz,Ar-H),7.36(d,1H,J＝8.0Hz Ar-H),7.26(d,1H,J＝6.0Hz,Ar-H),7.03-6.91(m,2H,Ar-H),3.97(s,2H,CH2),3.71(s,2H,CH2),2.90(t,2H,J＝8.0Hz,CH2),2.73(t,2H,J＝8.0Hz,CH2)；HRMS m/z:[M+H]+375.1558(calcd.375.1564).
example 8:
preparation of 2- ((1- (2,4, 6-trimethylphenyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (8)
Referring to the preparation method in example 1, in which p-chloroaniline was replaced with 2,4, 6-trimethylaniline, compound 8 was obtained as a pale yellow solid in a yield of 79.0%. The experimental data are as follows:
C23H25N5,yield 79.0％,pale yellow solid,m.p＝148.5-149.9℃；1H NMR(CDCl3,400MHz):δppm 8.56(s,1H,NH),7.56(s,1H,C＝CH),7.44(d,1H,J＝8.0Hz,Ar-H),7.23(s,1H,J＝12.0Hz,Ar-H),7.10-7.02(m,2H,Ar-H),6.98(s,2H,Ar-H),4.03(s,2H,Ar-H),3.73(s,2H,Ar-H),2.95(t,2H,J＝8.0Hz,CH2),2.84(t,2H,J＝8.0Hz,CH2),2.35(s,3H,CH3),3.85(s,6H,CH3)；HRMS m/z:[M+H]+372.2177(calcd.372.2183).
example 9:
preparation of 2- ((1- (3, 4-dimethoxyphenyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (9)
Referring to the preparation method in example 1, wherein p-chloroaniline was replaced with 3, 4-dimethoxyaniline, compound 9 was obtained as a tan solid in 87.1% yield. The experimental data are as follows:
C22H23N5O2,yield 87.1％,brown yellow solid,m.p＝180.9-181.6℃；1H NMR(DMSO,400MHz):δppm 10.70(s,1H,NH),8.75(s,1H,C＝CH),7.50-7.43(m,2H,Ar-H),7.37(d,1H,J＝12.0Hz,Ar-H),7.27(d,1H,J＝8.0Hz,Ar-H),7.13(d,1H,J＝12.0Hz,Ar-H),7.04-6.91(m,2H,Ar-H),3.94(s,2H,CH2),3.87(s,3H,CH3),3.82(s,3H,CH3),3.71(s,2H,CH2),2.91(t,2H,J＝6.0Hz,CH2),2.74(t,2H,J＝6.0Hz,CH2)；HRMS m/z:[M+H]+390.1922(calcd.390.1925).
example 10:
preparation of 2- ((1- (3-isopropylphenyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (10)
Referring to the preparation method in example 1, in which p-chloroaniline was replaced with m-isopropylaniline, compound 10 was obtained as a tan solid in 73.7% yield. The experimental data are as follows:
C23H25N5,yield 73.7％,brown yellow solid,m.p＝167.0-168.9℃；1H NMR(CDCl3,400MHz):δppm 8.57(s,1H,NH),7.94(s,1H,C＝CH),7.56(s,1H,Ar-H),7.45-7.36(m,3H,Ar-H),7.26-7.21(m,1H,Ar-H),7.05(t,2H,J＝12.0Hz,Ar-H),3.94(s,2H,CH2),3.68(s,2H,CH2),3.94(s,2H,CH2),2.82(s,2H,CH2),1.27(d,7H,J＝8.0Hz,CH-CH3)；HRMS m/z:[M+H]+372.2180(calcd.372.2183).
example 11:
preparation of 2- ((1- (4, 6-dimethylpyridinyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (11)
Referring to the preparation method in example 1, wherein p-chloroaniline was replaced with 2-amino-4, 6-dimethylpyridine, compound 11 was obtained as a yellow solid in 73.0% yield. The experimental data are as follows:
C21H22N6,yield 73.0％,yellow solid,m.p＝176.6-178.2℃；1H NMR(CDCl3,400MHz):δppm11.43(s,1H,NH),8.25(s,1H,C＝CH),7.38(s,1H,Ar-H),7.36-7.09(m,3H,Ar-H),6.93(s,1H,Ar-H),6.90(s,1H,Ar-H),3.67(s,2H,CH2),3.63(s,2H,CH2),2.85(s,2H,CH2),2.73(s,2H,CH2),2.49(s,3H,CH3),2.47(s,3H,CH3)；HRMS m/z:[M+H]+359.1974(calcd.359.1979).
example 12:
preparation of 2- ((1- (2-chloropyridyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (12)
Referring to the preparation method in example 1, wherein p-chloroaniline was replaced with 2-chloro-3-aminopyridine, cyan solid compound 12 was prepared in 74.2% yield. The experimental data are as follows:
C19H17ClN6,yield 74.2％,cyan solid,m.p＝155.4-157.3℃；1H NMR(CDCl3,400MHz):δppm11.23(s,1H,NH),8.37(s,1H,C＝CH),8.35-8.12(m,2H,Ar-H),7.63-7.21(m,3H,Ar-H),6.94-6.91(m,2H,Ar-H),3.65(s,2H,CH2),3.62(s,2H,CH2),2.81(s,2H,CH2),2.73(s,2H,CH2)；HRMS m/z:[M+H]+365.1273(calcd.365.1276).
example 13:
preparation of N- (4-bromophenyl) -3, 4-dihydro-1H-pyrido [3,4-b ] indole-2 (9H) -amide (13)
P-bromoaniline (1.72g,10mmol), 1,2,3, 4-tetrahydro-9H-pyrido [3,4-b ] indole (1,72g,10 mmol), triethylamine (5.5ml, 40mmol) and triphosgene (100.9mg, 0.34mmol) were added to a reaction flask in this order under nitrogen atmosphere, reacted at room temperature for 24 hours, water was added to terminate the reaction, dichloromethane was extracted, the organic phases were combined, the solvent was evaporated under reduced pressure, and column chromatography (DCM: MeOH: 80:1, volume ratio) was performed to obtain brown solid compound 13 with a yield of 44.0%. The experimental data are as follows:
C18H16BrN3O,yield 44.0％,brown-solid；1H NMR(DMSO,400MHz):δppm 10.88(s,1H,NH),8.86(s,1H,NH),7.49(d,2H,J＝8.0Hz,Ar-H),7.43(t,3H,J＝8.0Hz,Ar-H),7.33(d,1H,J＝4.0Hz,Ar-H),7.05(t,1H,J＝8.0Hz,Ar-H),6.98(t,1H,J＝8.0Hz,Ar-H),4.70(s,2H,NCH2CH2),3.83(t,2H,J＝4.0Hz,NCH2CH2),2.78(t,2H,J＝4.0Hz,NCH2)；HRMS m/z:[M+H]+370.0549(calcd.370.0550)。
example 14:
preparation of N- (isoquinolin-5-yl) -3, 4-dihydro-1H-pyrido [3,4-b ] indole-2 (9H) -amide (14)
Referring to the preparation method in example 13, wherein p-bromoaniline was replaced with 5-aminoisoquinoline, compound 14 was obtained as a brown solid in 50.5% yield. The experimental data are as follows:
C21H18N4O,yield 50.5％,brown solid；1H NMR(DMSO,400MHz):δppm 10.93(s,1H,NH),9.31(s,1H,NH),8.97(s,1H,Isoquinoline),8.49(d,1H,J＝8.0Hz,Isoquinoline),7.93(d,1H,J＝8.0Hz,Isoquinoline),7.70(m,3H,J＝7.62-7.79Hz,Isoquinoline),7.45(d,1H,J＝12.0Hz,Ar-H),7.34(d,1H,J＝8.0Hz,Ar-H),7.00(m,2H,J＝7.67-7.70Hz,Ar-H),4.79(s,2H,NCH2CH2),3.94(t,2H,J＝8.0Hz,NCH2CH2),2.86(t,2H,J＝8.0Hz,NCH2).HRMS m/z:[M+H]+343.1551(calcd.343.1553)。
example 15:
preparation of N- (2-chloropyridin-3-yl) -3, 4-dihydro-1H-pyrido [3,4-b ] indole-2 (9H) -amide (15)
Referring to the preparation method in example 13, wherein p-bromoaniline was replaced with 2-chloro-3-aminopyridine, compound 15 was obtained as a brown solid in 49.0% yield. The experimental data are as follows:
C17H15ClN4O,yield 49％,white solid；1H NMR(DMSO,400MHz):δppm 10.92(s,1H,NH),8.56(s,1H,NH),8.18(m,1H,J＝8.17-8.19Hz,Ar-H),7.98(m,1H,J＝7.96-7.99Hz,Ar-H),7.38(m,3H,J＝7.31-7.44Hz,Pyridine),7.03(m,2H,J＝6.96-7.09Hz,Ar-H),4.73(s,2H,NCH2CH2),3.86(t,2H,J＝8.0Hz,NCH2CH2),2.81(t,2H,J＝6.0Hz,NCH2).HRMS m/z:[M+H]+327.1006(calcd.327.1007)。
example 16:
preparation of N- (3-chloro-4-methylphenyl) -3, 4-dihydro-1H-pyrido [3,4-b ] indole-2 (9H) -amide (16)
Referring to the preparation method in example 13, wherein p-bromoaniline was replaced with 3-chloro-4-methylaniline, compound 16 was obtained as a bright brown solid in a yield of 25.5%. The experimental data are as follows:
C19H18ClN3O,yield 25.5％,light-brown solid,1H NMR(DMSO,400MHz):δppm 10.92(s,1H,NH),8.86(s,1H,NH),7.66(s,1H,Ar-H),7.40(d,1H,J＝8.0Hz,Ar-H),7.36(d,1H,J＝8.0Hz,Ar-H),7.31(d,1H,J＝8.0Hz,Ar-H),7.19(d,1H,J＝8.0Hz,Ar-H),7.04(t,1H,J＝8.0Hz,Ar-H),6.96(t,1H,J＝8.0Hz,Ar-H),4.68(s,2H,NCH2CH2),3.82(t,2H,J＝4.0Hz,NCH2CH2),2.76(t,2H,J＝4.0Hz,NCH2),2.24(s,3H,Ar-CH3)；HRMS m/z:[M+H]+340.1209(calcd.340.1211)。
example 17:
preparation of N- (4-tert-butylphenyl) -3, 4-dihydro-1H-pyrido [3,4-b ] indole-2 (9H) -amide (17)
Referring to the preparation method in example 13, wherein p-bromoaniline was replaced with 4-tert-butylaniline, compound 17 was obtained as a brown solid in a yield of 23.5%. The experimental data are as follows:
C22H25N3O,yield 23.5％,light-brown solid；1H NMR(DMSO,400MHz):δppm 10.88(s,1H,NH),8.65(s,1H,NH),7.42(d,2H,J＝12.0Hz,Ar-H),7.38(s,1H,Ar-H),7.33(d,1H,J＝8.0Hz,Ar-H),7.26(d,1H,J＝8.0Hz,Ar-H),7.05(t,1H,J＝8.0Hz,Ar-H),6.98(t,1H,J＝8.0Hz,Ar-H),4.69(s,2H,NCH2CH2),3.83(t,2H,J＝4.0Hz,NCH2CH2),2.77(t,2H,J＝4.0Hz,NCH2),1.26(s,9H,C(CH3)3)；HRMS m/z:[M+H]+348.2068(calcd.348.2070)。
example 18:
preparation of N- (4-trifluoromethylphenyl) -3, 4-dihydro-1H-pyrido [3,4-b ] indole-2 (9H) -amide (18)
Referring to the preparation method in example 13, wherein p-bromoaniline was replaced with 4-trifluoromethylaniline, compound 18 was obtained as a white solid in 24.5% yield. The experimental data are as follows:
C19H16F3N3O,yield 24.5％,white solid；1H NMR(DMSO,400MHz):δppm 10.89(s,1H,NH),9.12(s,1H,NH),7.72(d,1H,J＝8.0Hz,Ar-H),7.60(d,1H,J＝8.0Hz,Ar-H),7.42(d,1H,J＝8.0Hz,Ar-H),7.31(d,1H,J＝8.0Hz,Ar-H),7.06(t,1H,J＝8.0Hz,Ar-H),6.89(t,1H,J＝8.0Hz,Ar-H),4.72(s,2H,NCH2CH2),3.86(t,2H,J＝4.0Hz,NCH2CH2),2.79(t,2H,J＝4.0Hz,NCH2)；HRMS m/z:[M+H]+360.1317(calcd.360.1318).
example 19:
preparation of N- (2,4, 6-trichlorophenyl) -3, 4-dihydro-1H-pyrido [3,4-b ] indole-2 (9H) -amide (19)
Referring to the preparation method in example 13, wherein p-bromoaniline was replaced with 2,4, 6-trichloroaniline, compound 19 was obtained as a bright yellow solid in 21.5% yield. The experimental data are as follows:
C18H14Cl3N3O,yield 21.5％,light-yellow solid；1H NMR(DMSO,400MHz):δppm 10.88(s,1H,NH),8.67(s,1H,NH),7.71(s,2H,Ar-H),7.42(d,1H,J＝8.0Hz,Ar-H),7.31(d,1H,J＝8.0Hz,Ar-H),7.05(t,1H,J＝8.0Hz,Ar-H),6.97(t,1H,J＝8.0Hz,Ar-H),4.69(s,2H,NCH2CH2),3.84(t,2H,J＝4.0Hz,NCH2CH2),2.79(t,2H,J＝4.0Hz,NCH2)；HRMS m/z:[M+H]+394.0273(calcd.394.0275).
example 20:
preparation of N- (2, 4-dimethylphenyl) -3, 4-dihydro-1H-pyrido [3,4-b ] indole-2 (9H) -amide (20)
Referring to the preparation method in example 13, wherein p-bromoaniline was replaced with 2, 4-dimethylaniline, compound 20 was obtained as a bright yellow solid in 26.4% yield. The experimental data are as follows:
C20H21N3O,yield 26.4％,light-brown solid；1H NMR(DMSO,400MHz):δppm 10.88(s,1H,NH),8.19(s,1H,NH),7.42(d,1H,J＝8.0Hz,Ar-H),7.32(d,1H,J＝8.0Hz,Ar-H),7.06(t,1H,J＝8.0Hz,Ar-H),6.99(d,1H,J＝8.0Hz,Ar-H),6.94(d,1H,J＝8.0Hz,Ar-H),4.68(s,2H,NCH2CH2),3.82(t,2H,J＝4.0Hz,NCH2CH2),2.77(t,2H,J＝4.0Hz,NCH2),2.25(s,3H,Ar-CH3),2.13(s,3H,Ar-CH3)；HRMS m/z:[M+H]+320.1756(calcd.320.1757).
example 21:
a tablet containing 2- ((1- (4-chlorophenyl) -1H-1,2, 3-triazol-4-yl) methyl) -2,3,4, 9-tetrahydro-1H-pyrido [3,4-b ] indole (Compound 1), the contents of each raw material in each tablet (0.1g) are as follows:
the preparation method of the tablet comprises the following steps: mixing the raw materials and the auxiliary materials according to a conventional method in the field, granulating, drying and tabletting to obtain the tablet. Application test: the following are the data from pharmacological experiments with some of the compounds of the invention:
1. antagonistic Activity screening of Compounds 1 to 20 of the present invention against TRPV1 receptor
By adopting an aequorin reporter gene detection technology, the cell strain stably co-expresses aequorin and a TRPV1 receptor. Intracellular Ca when the receptor is excited2+Increase in Ca2+Coelenterazine reconstitutes the photoprotein, producing a bioluminescent effect at 469 nm. By measuring the rapid chemiluminescent signal produced by the release of stimulated intracellular calcium, test samples can be screened for effects on the TRPV1 receptor.
The TRPV1 antagonistic activity screening experiment of the compound comprises the following steps: test compounds and capsaicin were brought to an initial concentration of 10mM in DMSO and diluted to a test concentration of 0.1mM in Try's solution, where the capsaicin was diluted to 250 nM. The initial concentration of calcium ion fluorescent probe was 5mM and was diluted to a concentration of 0.05mM with HBSS containing 33mg Pluronic F-127 per ml. Approximately 10000 HEK-293-TRPV1 cells per well were incubated at 37 ℃ with 10. mu.l of 0.05mM calcium ion fluorescent probe. After 20 minutes, 30. mu.l of HBSS containing 1% FBS was added and incubation was continued for 40 minutes. After 40 minutes, the HBSS and other fluids are aspirated from the wells and the wells are washed with Taiwan's solution, followed by 40 microliters of test compound at a concentration of 0.1mM per well. 3 duplicate wells were set for each compound, 3 of which were incubated at 37 ℃ for 30 minutes with only Tschmann's solution as a blank, and fluorescence intensity was measured at 488nm for excitation and 526nm for emission. Cells were then incubated at 37 ℃ for 30 minutes with 10. mu.l of capsaicin at a concentration of 250nM per well and fluorescence intensity was measured at an excitation wavelength of 488nM and an emission wavelength of 526 nM. The relative concentration of intracellular calcium ions is characterized by calculating the difference of fluorescence intensity before and after each group of capsaicin is added, so as to detect the antagonism degree of the compound on the capsaicin, and further detect the TRPV1 receptor of the compoundThe degree of antagonistic activity. Part of the compounds being at 10-5Antagonistic activity against TRPV1 receptor at mol dose results are shown in table 1.
Table 1 screening of partial compounds for TRPV1 receptor antagonistic activity
Note: inhibition rate (blank difference-experimental group difference)/blank difference 100%
Fluorescence intensity after adding capsaicin in blank group-fluorescence intensity before adding capsaicin in blank group
The difference between the experimental group and the fluorescence intensity after adding capsaicin-the fluorescence intensity before adding capsaicin
NE: the blank control group had an inhibition ratio of 0.
The test results in table 1 show that: the inhibition rates of tested compounds 1 to 20 on TRPV1 are all more than 50%, which indicates that the tested compounds have TRPV1 inhibitory activity.
2. Effect of Compounds 1 to 20 of the invention on three mouse pain models
The mouse licking experiment: mice were randomly grouped by weight, 6 per group. The oral gavage is carried out 30 minutes before the test, the dosage is 30mg/kg, and the blank group is provided with 0.5 percent CMC-Na with equal volume. For the test, 20. mu.L (1.6. mu.g/20. mu.L) of capsaicin was injected subcutaneously into the right dorsum of the mouse, and the total length of time (unit: sec) that the mouse licks the right foot within 5 minutes was recorded.
Mouse writhing experiment: mice were randomly grouped by weight, 6 per group. The oral gavage is carried out 30 minutes before the test, the dosage is 30mg/kg, and the blank group is provided with 0.5 percent CMC-Na with equal volume. When in test, the mouse is injected with 0.6 percent acetic acid solution in the abdominal cavity, and the times of writhing reaction (belly concave, hind limb stretching and hip lifting) of the mouse within 15 minutes are recorded.
Mouse tail-shortening experiment: mice were randomly grouped by weight, 6 per group. The tail end of the mouse tail is immersed in a hot water bath at 52 ℃, the tail contraction response time of the mouse is recorded, the two times of measurement are carried out at an interval of 10 minutes, the average value is used as the basic pain threshold of the mouse, and the time for immersing the mouse tail in the hot water does not exceed 12 seconds. 30 minutes after the basal pain threshold was determined, each group was orally gavaged at a dose of 30mg/kg, and the blank group was given an equal volume of 0.5% CMC-Na. After half an hour of administration, the basal pain threshold was measured and the tail-shortening response time was measured half an hour after administration, and the average value was the pain threshold after administration. The percent maximum analgesic effect (MPE%) for each group was calculated as (basal pain threshold-post-dose pain threshold)/(cut-off time-basal pain threshold) × 100, with a cut-off time of 12 seconds.
TABLE 2 analgesic Activity of partial Compounds in three mouse pain models
Note: t-test, p <0.05, p <0.01, p <0.001 compared to blank group. High potency selective TRPV1 antagonist BCTC: n- (4-tert-butylphenyl) -4- (3-chloropyridin-2-yl) piperazine-1-carboxamide
The test results in table 2 show that: in three analgesic models, partial compounds of the invention such as 1,5,6,7,13,18,19 and the like have very significant difference compared with a blank group, wherein the analgesic activity of the preferred compound 1 is superior to that of a positive control BCTC, and the compound has stronger analgesic effect.
3. Effect of Compounds 1 to 20 of the invention on mouse body temperature
Mice were randomly grouped by weight, 6 per group. Each group was orally administered at a dose of 30mg/kg by gavage, and the blank group was administered with 0.5% CMC-Na in an equal volume. Mouse body temperature was measured 0min, 30 min, 60 min, 90 min, 120 min after administration.
The test result shows that: compared with 0 minute after the positive control BCTC is administrated, the difference is very obvious; compared with 0 minute after the compound 1-5 test groups are administrated, the compound 1-5 test groups have no significant difference with the blank group, and the body temperature of the mouse has no obvious change. The partial compound of the invention is proved to have little influence on the body temperature of mice.
The pharmacological data show that the compound of the general formula (I) has stronger analgesic effect compared with positive control BCTC, and the preferable compound has almost no side effect of body temperature rise.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910053921.7A CN109761974B (en) | 2019-01-21 | 2019-01-21 | 1,2,3, 4-tetrahydro-9H-pyrido [3,4-b ] indole TRPV1 antagonist and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910053921.7A CN109761974B (en) | 2019-01-21 | 2019-01-21 | 1,2,3, 4-tetrahydro-9H-pyrido [3,4-b ] indole TRPV1 antagonist and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109761974A CN109761974A (en) | 2019-05-17 |
| CN109761974B true CN109761974B (en) | 2021-05-14 |
Family
ID=66454983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910053921.7A Active CN109761974B (en) | 2019-01-21 | 2019-01-21 | 1,2,3, 4-tetrahydro-9H-pyrido [3,4-b ] indole TRPV1 antagonist and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109761974B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111454233B (en) * | 2020-05-08 | 2023-01-24 | 河南大学 | 4- (2- (pyrrolidine/piperidine-1-yl) benzyl) -piperazinylurea TRPV1 antagonist and preparation and application thereof |
| CN111423432B (en) * | 2020-05-11 | 2023-01-24 | 河南大学 | (S) -4/5-phenyl-2- (pyrrolidine-2-yl) thiazole TRPV1 antagonist and preparation and application thereof |
| CN113233996B (en) * | 2021-05-20 | 2022-05-20 | 河南大学 | Novel TRPV1 antagonist/FAAH inhibitor dual-target drug and its preparation method and application |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004113300A1 (en) * | 2003-06-23 | 2004-12-29 | Ono Pharmaceutical Co., Ltd. | Novel tricyclic heterocycle compound |
| WO2006123242A1 (en) * | 2005-05-18 | 2006-11-23 | Pfizer Limited | 1, 2, 4 -triazole derivatives as vasopressin antagonists |
| CN101379041A (en) * | 2006-02-03 | 2009-03-04 | 赛诺菲-安万特 | Tricyclic N-heteroaryl-amide derivatives containing benzimidazole structural units, their preparation and their therapeutic use |
| WO2009069132A2 (en) * | 2007-11-29 | 2009-06-04 | Ramot At Tel Aviv University Ltd. | Novel reverse transcriptase inhibitors |
| CN111454233A (en) * | 2020-05-08 | 2020-07-28 | 河南大学 | 4- (2- (pyrrolidine/piperidine-1-yl) benzyl) -piperazinylurea TRPV1 antagonist and preparation and application thereof |
-
2019
- 2019-01-21 CN CN201910053921.7A patent/CN109761974B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004113300A1 (en) * | 2003-06-23 | 2004-12-29 | Ono Pharmaceutical Co., Ltd. | Novel tricyclic heterocycle compound |
| WO2006123242A1 (en) * | 2005-05-18 | 2006-11-23 | Pfizer Limited | 1, 2, 4 -triazole derivatives as vasopressin antagonists |
| CN101379041A (en) * | 2006-02-03 | 2009-03-04 | 赛诺菲-安万特 | Tricyclic N-heteroaryl-amide derivatives containing benzimidazole structural units, their preparation and their therapeutic use |
| WO2009069132A2 (en) * | 2007-11-29 | 2009-06-04 | Ramot At Tel Aviv University Ltd. | Novel reverse transcriptase inhibitors |
| CN111454233A (en) * | 2020-05-08 | 2020-07-28 | 河南大学 | 4- (2- (pyrrolidine/piperidine-1-yl) benzyl) -piperazinylurea TRPV1 antagonist and preparation and application thereof |
Non-Patent Citations (5)
| Title |
|---|
| Reaction of tetrahydro-β-carboline-1-carboxylic acid with isocyanates and isothiocyanates. Synthesis of 1-alkyl- or arylcarbamoyl-β-carbolines;Lopez-Rodriguez, Maria L. 等;《Heterocycles》;19941231;第37卷(第2期);化合物VIb * |
| RN：1022361-86-9;ACS;《STN Registry数据库》;20080525;化合物RN：1991560-79-2 * |
| RN：1923502-86-6;ACS;《STN Registry数据库》;20160102;化合物RN：1022361-86-9 * |
| RN：1991560-79-2;ACS;《STN Registry数据库》;20120912;化合物RN：1923502-86-6 * |
| Tetrahydro-β-carboline derivatives targeting fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channels;Giorgio Ortar 等;《Bioorganic & Medicinal Chemistry Letters》;20121112;第23卷(第1期);第138-142页，尤其是第139图1，第140页表1，第138页左栏第1段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109761974A (en) | 2019-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109761974B (en) | 1,2,3, 4-tetrahydro-9H-pyrido [3,4-b ] indole TRPV1 antagonist and application thereof | |
| CN105669564B (en) | Carbamide compounds, its preparation method, pharmaceutical composition, intermediate and its application | |
| WO2016184434A1 (en) | Pyrido-azaheterecydic compound and preparation method and use thereof | |
| CN102216300B (en) | Compounds and compositions as protein kinase inhibitors | |
| CN111454233B (en) | 4- (2- (pyrrolidine/piperidine-1-yl) benzyl) -piperazinylurea TRPV1 antagonist and preparation and application thereof | |
| JP7557890B2 (en) | Immunosuppressants, their manufacturing method and applications | |
| PL184446B1 (en) | Substituted derivatives of imidazolydinodione-2,4, method of obtaining them and pharmaceutic preparation | |
| CN103833759A (en) | Pteridinone derivatives as BLK and FLT3 inhibitors and applications thereof | |
| CN105367565B (en) | Piperazine (pyridine) cyclohexyl derivatives and its application for treating Mental disease | |
| CN111423432B (en) | (S) -4/5-phenyl-2- (pyrrolidine-2-yl) thiazole TRPV1 antagonist and preparation and application thereof | |
| TW200524599A (en) | Substituted tricyclic heterocycles and their uses | |
| RU2303037C2 (en) | Derivatives of pyridine and medicinal agent based on thereof possessing selective blocking activity with respect to subspecies of nmda-receptors | |
| EP2895467A1 (en) | Crystalline compounds | |
| CN113307791B (en) | Pyrimidylpiperazine urea TRPV1 antagonistic/MOR agonistic double-target compound and preparation method and application thereof | |
| JP6680888B2 (en) | Pyridinol derivative or pharmaceutically acceptable salt thereof and pharmaceutical composition containing the same as an active ingredient | |
| CN110734391A (en) | 2, 3-diketone indole compound and preparation method and application thereof | |
| CN102617478B (en) | Synthesis of benzimidazole, oxazole and thiazole derivatives and application thereof | |
| CN109096251B (en) | Compounds with dual histamine receptor antagonistic activity and uses | |
| US9593113B2 (en) | Imide and acylurea derivatives as modulators of the glucocorticoid receptor | |
| CN107793350A (en) | Fragrant ethyl piperidine radical derivative and its schizoid application for the treatment of | |
| CN112457265A (en) | Tetrazole derivative, preparation method thereof, pharmaceutical composition containing tetrazole derivative and application of pharmaceutical composition | |
| WO2013147215A1 (en) | 4-alkanoylamino-3-pyrazolone derivative | |
| TWI867137B (en) | Biphenyl fluorinated double bond derivatives and preparation methods thereof and pharmaceutical applications | |
| CN118063489A (en) | Evodiamine compounds and pharmaceutical uses thereof | |
| CN108727404B (en) | Thieno[3,2-d]pyrimidine compound, its preparation method and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |